Iodine‐131‐meta‐iodobenzylguanidine therapy for patients with newly diagnosed high‐risk neuroblastoma

BACKGROUND: Patients with newly diagnosed high‐risk (HR) neuroblastoma (NBL) still have a poor outcome, despite multi‐modality intensive therapy. This poor outcome necessitates the search for new therapies, such as treatment with (131)I‐meta‐iodobenzylguanidine ((131)I‐MIBG). OBJECTIVES: To assess t...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cochrane Database Syst Rev
Huvudupphovsmän: Kraal, Kathelijne CJM, van Dalen, Elvira C, Tytgat, Godelieve AM, Van Eck‐Smit, Berthe LF
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley & Sons, Ltd 2017
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6478145/
https://ncbi.nlm.nih.gov/pubmed/28429876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD010349.pub2
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk